Retinal degeneration is one of the leading causes of vision loss and blindness in the world. Some retinopathies are caused by autoimmune processes. Autoantibodies against retinal proteins are strongly associated with retinal degeneration in patients with autoimmune and paraneoplastic retinopathies. In these retinopathies, antibody-triggered apoptotic death of retinal cells progressively causes significant tissue damage, loss of vision, and blindness. Age is the strongest risk factor for the incidence of retinopathies in adult Americans. Our studies show that the average age of patients with cancer-associated retinopathy (CAR) or autoimmune retinopathy (AR) is about 62 years. Currently, there is no approved therapy for treating these patients and the corticosteroid and immunomodulation therapies that are frequently offered are ineffective. Moreover, anti-aging mechanisms have not been factored into designing therapeutics for visual loss. We propose a novel non-steroidal protection treatment using the anti-aging drug resveratrol (RES), a polyphenolic phytoalexin found in purple grapes, for treating autoimmune retinopathies. We hypothesize that RES induces anti-apoptotic mechanisms that confer neuroprotection against antibody-induced cell death in the retinas of patients with CAR and AR. The long-term goal of this study is to identify safe and effective therapeutic compounds like RES for treatment of autoimmune diseases of the eye and to define their protective mechanisms at the molecular level. The main objectives of this study are to define a mechanism by which RES prevents the expression of apoptotic proteins in the rat retina, induces anti-aging SIRT1 protein expression, and how aging influences the expression of SIRT1 in a rat model for CAR. To achieve these objectives, the following specific aims are proposed:
(Aim 1) To determine the therapeutic effects of RES against antibody-induced retinal cell death in Sprague-Dawley (SD) rats, and (Aim 2) To determine the effects of retinal aging on antibody-induced retinopathy and define the mechanism of RES protection using young and old SD rats.

Public Health Relevance

Retinal degeneration is one of the leading causes of vision loss and blindness in the world. Some retinopathies are caused by autoimmune processes. Autoantibodies against retinal proteins are strongly associated with retinal degeneration in patients with autoimmune and paraneoplastic retinopathies. Age is the strongest risk factor for the incidence of retinopathies in adult Americans. No approved treatment is currently available for these patients and the corticosteroid therapies that are frequently offered are ineffective. We propose to examine in our in vivo studies a novel non-steroidal anti-aging drug resveratrol for the treatment of autoimmune retinopathies. Also, propose to determine the effects of aging on antibody-induced retinopathy and define the mechanism of resveratrol protection using young and old SD rats.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21EY018708-01A2
Application #
7659323
Study Section
Special Emphasis Panel (ZRG1-CB-G (90))
Program Officer
Shen, Grace L
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$230,934
Indirect Cost
Name
Oregon Health and Science University
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Copenhaver, Philip F; Anekonda, Thimmappa S; Musashe, Derek et al. (2011) A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug. Dis Model Mech 4:634-48
Anekonda, Thimmappa S; Quinn, Joseph F; Harris, Christopher et al. (2011) L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 41:62-70
Anekonda, Thimmappa S; Wadsworth, Teri L; Sabin, Robert et al. (2011) Phytic acid as a potential treatment for alzheimer's pathology: evidence from animal and in vitro models. J Alzheimers Dis 23:21-35
Anekonda, Thimmappa S; Quinn, Joseph F (2011) Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine. Biochim Biophys Acta 1812:1584-90
Anekonda, T S (2009) The Benefits of Calorie Restriction and Calorie Restriction Mimetics as Related to the Eye. Open Longev Sci 3:28-37